Triptorelin

Mechanism

A long-acting GnRH agonist used medically for prostate cancer and endometriosis. In the peptide community, a single low dose is sometimes used for post-cycle therapy (PCT) to "restart" the HPTA axis after anabolic steroid use. Works by first stimulating, then suppressing, and then allowing recovery of gonadotropin release.

Effects

**Reproductive/Endocrine System (Tier 1 — FDA-approved):** Triptorelin is a synthetic GnRH agonist (decapeptide analog of natural GnRH) with 100x greater potency than native GnRH. In continuous/depot administration, it produces initial "flare" (LH/FSH surge for 1-2 weeks) followed by profound pituitary desensitization and chemical castration (testosterone < 20 ng/dL). This biphasic response is the basis for both its therapeutic use (prostate cancer, endometriosis, precocious puberty) and its controversial single-dose PCT application. **Chemical Castration Phase (Tier 1):** After initial flare, continuous GnRH receptor stimulation causes receptor downregulation and desensitization of gonadotrophs. LH drops below detectable levels. Testosterone reaches castrate levels within 2-4 weeks. Effects of depot formulations last 1-6 months depending on formulation (Trelstar 3.75mg = 1 month, 11.25mg = 3 months, 22.5mg = 6 months). **Single-Dose PCT Effect (Tier 2-3 — Controversial):** A single low-dose injection (100mcg) of triptorelin produces ONLY the initial flare — a massive, acute LH/FSH surge — without sustained exposure needed for desensitization. This LH surge floods the Leydig cells with stimulation, acutely driving testosterone production. The theory is that this "shock" to the HPG axis can restart endogenous testosterone production after AAS-induced suppression. The surge typically peaks at 4-8 hours and subsides within 24-48 hours, but the downstream effects on testicular function may persist for weeks. **Prostate Cancer (Tier 1 — Primary Indication):** Androgen deprivation therapy (ADT) via chemical castration. Used as first-line hormonal therapy for advanced/metastatic prostate cancer. Achieves castrate testosterone levels comparable to bilateral orchiectomy. Combined with anti-androgens (bicalutamide, enzalutamide) in many protocols. **Other FDA-approved Uses (Tier 1):** Central precocious puberty (depot formulation suppresses premature HPG axis activation), endometriosis (3-6 month courses reduce estrogen-dependent lesions), uterine fibroids (pre-surgical GnRH agonist therapy to shrink fibroids).

Practitioner Guide

**The Controversial Single-Dose PCT Protocol:** - Dose: 50-100mcg triptorelin SC or IM as a SINGLE injection - Timing: administered after AAS clearance (typically 2 weeks after last testosterone injection, or 3-5 half-lives after last compound) - CRITICAL: this is a ONE-TIME dose. Repeating the injection risks cumulative pituitary desensitization → chemical castration - Expected response: massive LH surge within 4-8 hours, testosterone recovery beginning within 1-2 weeks - Some practitioners follow the triptorelin shot with 2-4 weeks of low-dose Clomid (25mg/day) or Nolvadex (20mg/day) to support the recovery **Why It Works (When It Works):** - The single low dose produces the "flare" phase only — a supraphysiological LH/FSH pulse - This acute pulse is thought to "reboot" Leydig cell function that has been dormant during AAS use - Unlike HCG (which provides LH-like stimulation directly), triptorelin reactivates the ENTIRE HPG cascade from the pituitary down - The magnitude of the LH surge exceeds what Clomid or Nolvadex can produce through estrogen blockade alone **Why It Is Dangerous If Repeated:** - A second dose within 2-4 weeks risks inducing pituitary desensitization — the exact mechanism used for chemical castration in prostate cancer - If desensitization occurs, the patient enters a WORSE state than before PCT — castrate testosterone levels with no natural recovery for months - There is NO reliable way to predict where the threshold between "helpful flare" and "harmful desensitization" lies for any individual - Even a single dose at too-high a level (e.g., using a full 3.75mg depot formulation) will cause chemical castration lasting weeks to months **Documented Case Reports of Successful HPTA Restarts:** - The most cited case: a 1996 case report of a bodybuilder with prolonged azoospermia after years of AAS use who recovered spermatogenesis after single-dose triptorelin 100mcg (documented by Dr. Giasolli, published in Italian medical literature) - Multiple forum-documented protocols (2005-present) describe successful PCT with 100mcg triptorelin in men who failed traditional Clomid/Nolvadex PCT - Dr. Michael Scally's "Power PCT" protocol included triptorelin as an option alongside HCG + Clomid + Nolvadex for severe HPTA suppression cases - Limitation: these are case reports and anecdotes — no RCTs comparing triptorelin PCT to standard PCT **Comparison to Traditional Clomid/Nolvadex PCT:** - Traditional PCT: Clomid 50/50/25/25mg (4 weeks) + Nolvadex 40/40/20/20mg (4 weeks) → gradual LH/FSH recovery over 4-6 weeks - Triptorelin PCT: single injection → acute LH surge → faster initial testosterone spike, but less "sustained support" - Combination approach (some practitioners): triptorelin 100mcg on day 1, then Nolvadex 20mg/day for 4 weeks → best of both? - Honest assessment: traditional PCT is SAFER and MORE PREDICTABLE. Triptorelin should be reserved for cases where standard PCT has failed **Prostate Cancer — Standard of Care:** - Trelstar depot: 3.75mg IM monthly, 11.25mg IM q3 months, or 22.5mg IM q6 months - Always co-administer anti-androgen (bicalutamide 50mg/day) for first 2-4 weeks to block testosterone flare - Monitor PSA, testosterone levels quarterly - ADT side effects: hot flashes, fatigue, bone density loss, metabolic syndrome, mood changes, sexual dysfunction **Absolute Contraindications for PCT Use:** - NEVER use depot formulations (3.75mg+) for PCT — only 50-100mcg of the base peptide - NEVER repeat the dose — one shot only - Do not use in patients with unknown pituitary pathology - Do not use in patients still on active AAS (compounds must be cleared first)

Dosing Protocols

Contraindications & Cautions

• hard stop — Pregnancy
  Triptorelin is teratogenic. GnRH agonists cause fetal harm by disrupting the hormonal environment critical for fetal development. Labeled contraindication (Trelstar prescribing information).
  Action: Absolutely contraindicated. Do not use during pregnancy. Verify negative pregnancy test before administration.
• hard stop — Breastfeeding
  GnRH agonist suppresses sex hormones required for lactation. May inhibit milk production.
  Action: Do not use while breastfeeding.
• hard stop — Under 18 years of age
  GnRH agonist. Not for unsupervised use in minors.
  Action: Do not provide to individuals under 18.
• requires physician — Osteoporosis
  Long-term GnRH agonist use causes significant bone mineral density loss due to hypogonadism-induced estrogen/testosterone suppression. Patients with existing osteoporosis or osteopenia are at high risk for fractures.
  Action: Requires bone density assessment (DEXA scan) before initiation. Consider calcium, vitamin D, and bisphosphonate co-therapy. Monitor BMD during treatment.
• monitor — Depression or mood disorders
  Sex hormone suppression from GnRH agonists commonly worsens mood, causes emotional lability, and may precipitate or exacerbate depression. Suicidal ideation has been reported.
  Action: Monitor mood closely. Ensure mental health support is in place. Consider psychiatric evaluation before and during use.
• requires physician — Cardiovascular disease
  Androgen deprivation therapy with GnRH agonists is associated with increased cardiovascular risk including myocardial infarction, stroke, and sudden cardiac death per FDA safety communication.
  Action: Requires cardiovascular evaluation before initiation. Monitor lipids, blood pressure, and glucose regularly. Cardiology consultation for patients with existing CVD.
• caution — Repeat dosing for PCT purposes
  Triptorelin for PCT (post-cycle therapy) should be a single low dose (100 mcg) to trigger LH/FSH rebound. Repeat doses or high doses will cause sustained pituitary downregulation and chemical castration — the OPPOSITE of the intended PCT effect.
  Action: Single low dose only for PCT. Do NOT repeat. Do NOT use depot formulations for PCT. Understand that multi-dose triptorelin causes castrate-level testosterone.

Evidence

• Triptorelin for advanced prostate cancer

  Heyns CF, Simonin MP, Grosgurin P, Schall R, Porchet HC (2003) — Expert Opinion on Pharmacotherapy

  Triptorelin (GnRH agonist) achieves medical castration through continuous GnRH receptor stimulation, producing initial testosterone flare followed by sustained suppression to castrate levels. Multiple Phase 3 trials demonstrated equivalence to surgical castration for advanced prostate cancer. Also approved for central precocious puberty and endometriosis. 3-month and 6-month depot formulations available.

  strong

• Sustained-release triptorelin for the treatment of advanced prostate cancer

  Heyns CF, Simonin MP, Grosgurin P, Schall R, Porchet HC (2003) — BJU International — PMID: 12631428

  Triptorelin 11.25 mg sustained-release depot achieved castrate testosterone levels (<50 ng/dL) in 96.1% of advanced prostate cancer patients maintained over 9 months. Testosterone suppression was achieved by day 29 on average. PSA reduction correlated with testosterone suppression. Well-tolerated with hot flashes as most common side effect.

  strong

Research Summary

**Tier 1 — FDA-approved (multiple indications):** - FDA approved as Trelstar (depot formulations) for advanced prostate cancer (2000), central precocious puberty, endometriosis - Extensive phase III data in prostate cancer: achieves castrate testosterone (< 50 ng/dL) in >96% of patients - Pivotal prostate cancer trials: comparable efficacy to leuprolide and goserelin - Well-established safety profile over 25+ years of clinical use in depot form **Tier 2 — Established Clinical Evidence:** - GnRH agonist "flare" response is well-characterized in endocrinology literature — acute LH/FSH surge is a known pharmacological effect - Flare magnitude: single dose of GnRH agonist produces LH rise of 5-15x baseline within 4-8 hours - Pituitary desensitization requires sustained/repeated exposure (typically >7-14 days of continuous agonist) - Established that single acute GnRH agonist exposure does NOT cause desensitization (basis for IVF trigger with leuprolide) **Tier 3 — PCT Use (Case Reports/Anecdotal):** - Original case report: Giasolli et al. — single bodybuilder with AAS-induced azoospermia, recovered spermatogenesis after 100mcg triptorelin (Italian literature, 1996) - No RCTs comparing triptorelin PCT to standard SERMs or HCG-based PCT - Dr. Scally's "Power PCT" concept: theoretical framework for using GnRH agonist pulse to restart HPTA - Underground/forum evidence: hundreds of self-reported cases of successful single-dose triptorelin PCT (selection bias — failures are underreported) - Risk documentation: multiple case reports of men who used full depot doses (3.75mg+) for PCT and experienced months of chemical castration - Academic perspective: the pharmacology is sound (single dose = flare only), but the margin of safety is narrow and no controlled studies exist - Some endocrinologists have described using the principle (single GnRH agonist pulse) in clinical practice for severe hypogonadotropic hypogonadism recovery, but this is not standardized